ArticleAmerican journal of translational research2022
Expression of LncRNA KCNQ1Ot1 in diabetic nephropathy and its correlation with MEK/ERK signaling pathway.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- The versatile roles of long non-coding RNAs in kidney disease.Nature reviews. Nephrology · 2026Review
- Integrative analysis of circ_DLGAP4, lncRNA KCNQ1OT1, and the miR-9/SOX7 interaction network in chronic kidney disease progression: a case-control study.Functional & integrative genomics · 2026Observational
- Knockdown of circ_0000372 elevates PD-L1 level through sponging miR-488-3p to restrain cell viability, motility and immune escape in gastric cancer.Journal of molecular histology · 2025Article
- Investigation of the Impact of miRNA-7151 and a Mutation in Its Target Gene lncRNABiomedicines · 2025Article
- Silencing LncRNA SNHG14 alleviates renal tubular injury via the miR-483-5p/HDAC4 axis in diabetic kidney disease.Hormones (Athens, Greece) · 2025Article
- Immunoglobulin heavy constant gamma 1 silencing decreases tonicity-responsive enhancer-binding protein expression to alleviate diabetic nephropathy.Journal of diabetes investigation · 2024Article
- LncRNA CASC15 inhibition relieves renal fibrosis in diabetic nephropathy through down-regulating SP-A by sponging to miR-424.Open medicine (Warsaw, Poland) · 2023Article
- The role of lncRNAs in regulation of DKD and diabetes-related cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the expression of LncRNA KCNQ1OT1 in diabetic nephropathy (DN), and its correlation with MEK/ERK signaling pathway.
methods148 patients with type 2 diabetes in our hospital were selected as research subjects, including 83 patients with simple type 2 diabetes (T2D group) and 65 patients with type 2 diabetes with DN (DN group). Another 50 non-diabetic patients were enrolled as the control group. The expressions of LncRNA KCNQ1OT1 and MEK/ERK signaling pathway related molecules in peripheral blood mononuclear cells (PBMCs) of the three groups of subjects were detected and their correlations were analyzed. In addition, 30 Wistar rats were divided into a control group, diabetes group and DN model group, and the expression of LncRNA KCNQ1OT1 and MEK/ERK signal pathway-related molecules in kidney tissue of the three groups was detected and compared.
resultsThe relative expression of LncRNA KCNQ1OT1, MEK-5 and ERK2 in the control group was lower than that of the T2D group and DN group (
conclusionThe expression of LncRNA KCNQ1OT1 in PBMCs of DN patients is abnormally increased, and may be a biomarker for the diagnosis and treatment of the disease. In addition, an abnormal increase of LncRNA KCNQ1OT1 is associated with the activation of the MEK/ERK signaling pathway.
Indexed as
Identifiers
35422925PMC8991120W4226330537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.